The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 07, 2025
Filed:
May. 23, 2019
Applicant:
Meharry Medical College, Nashville, TN (US);
Inventors:
Bindong Liu, Brentwood, TN (US);
Qiujia Shao, Brentwood, TN (US);
Assignee:
Meharry Medical College, Nashville, TN (US);
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/74 (2015.01); A61K 9/00 (2006.01); A61K 31/34 (2006.01); A61K 31/427 (2006.01); A61K 31/439 (2006.01); A61K 31/4418 (2006.01); A61K 31/513 (2006.01); A61K 31/52 (2006.01); A61K 31/537 (2006.01); A61K 31/5377 (2006.01); A61K 31/675 (2006.01); A61K 31/702 (2006.01); A61K 31/7072 (2006.01); A61K 31/715 (2006.01); A61K 38/16 (2006.01); A61K 38/21 (2006.01); A61K 45/06 (2006.01); A61K 47/60 (2017.01); A61P 31/18 (2006.01); C07H 3/06 (2006.01); C08B 37/00 (2006.01);
U.S. Cl.
CPC ...
A61K 35/74 (2013.01); A61K 9/0014 (2013.01); A61K 9/0019 (2013.01); A61K 31/34 (2013.01); A61K 31/427 (2013.01); A61K 31/439 (2013.01); A61K 31/4418 (2013.01); A61K 31/513 (2013.01); A61K 31/52 (2013.01); A61K 31/5377 (2013.01); A61K 31/675 (2013.01); A61K 31/702 (2013.01); A61K 31/7072 (2013.01); A61K 31/715 (2013.01); A61K 38/162 (2013.01); A61K 38/212 (2013.01); A61K 45/06 (2013.01); A61K 47/60 (2017.08); A61P 31/18 (2018.01); C07H 3/06 (2013.01); C08B 37/0003 (2013.01);
Abstract
Compositions of glycan strands and oligosaccharides derived from gram-positive bacteria and methods of use thereof are provided. The disclosed compositions have inhibitory activity toward both early and late stages of viral infection and transmission. The disclosed compositions may be used to treat and/or prevent infection and transmission of viruses, such as HIV, to upregulate one or both of AG3 and MX2, to enhance immune function, and/or to inhibit replication of a virus.